The QualityStocks Daily Tuesday, September 10th, 2019

Today's Top 3 Investment Newsletters

BUYINS.NET (FRAN) +101.55%

QualityStocks (MOMT) +87.25%

The Cervelle Group (MCTC) +45.90%

The QualityStocks Daily Stock List

BioCardia, Inc. (BCDA)

Zacks, StockTwits, Street Insider, Stockopedia, Stockhouse, MarketBeat, Capital Cube, Wallet Investor, AI Stock Finder, Dividend Investor, and Barchart reported earlier on BioCardia, Inc. (BCDA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioCardia, Inc. is a leader in the development of comprehensive solutions for cardiovascular regenerative therapies. Its biotherapeutic product candidates in clinical development are CardiAMP and CardiALLO cell therapies. BioCardia also partners with other biotherapeutic companies. This is to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. A clinical-stage regenerative medicine company, BioCardia is based in San Carlos, California. The Company lists on the OTC Markets’ OTCQB.

In addition, BioCardia offers the Helix biotherapeutic delivery system; and the Morph vascular access product line, which provides catheter products. BioCardia’s lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System. It provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications. These are heart failure that develops after a heart attack and chronic myocardial ischemia.

The Company’s second therapeutic candidate is the investigational CardiALLO™ Cell Therapy System. This is an allogeneic culture expanded "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. The therapy has the potential to be advanced for manifold clinical indications, including heart failure.

BioCardia announced this past May U.S. Food and Drug Administration (FDA) 510(k) clearance of the AVANCE™ steerable introducer product family, designed for introducing different cardiovascular catheters into the heart. This includes through the left side of the heart by way of the interatrial septum.

The AVANCE steerable introducer family leverages Morph “DNA” technology. This is an enhancement of the Company’s FDA-cleared Morph steerable introducer that adds several features that make the devices ideal for use in transseptal procedures and are designed to improve upon commercially-available offerings.

Last month, BioCardia announced that the European Patent Office issued the Company Patent No: 3063172 for “Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies.” BioCardia has an issued United States patent covering this technology, and also additional patents and patents pending for other proprietary technology related to its stem cell therapies in the U.S., Europe, Japan, China and India.

The Phase III pivotal CardiAMP™ Heart Failure Trial of BioCardia’s lead therapeutic candidate, the investigational CardiAMP™ Cell Therapy System, has added two new centers to the trial. It has also speeded up enrollment in the last quarter, with 23 world class U.S. centers participating and 49 patients enrolled to date.

BioCardia, Inc. (BCDA), closed Tuesday's trading session at $4.88, up 1.6667%, on 5,714 volume with 75 trades. The average volume for the last 3 months is 5,857 and the stock's 52-week low/high is $4.17000007/$17.50.

chart

Diversicare Healthcare Services, Inc. (DVCR)

Stock Twits, Zacks, Street Insider, Investing.com, MacroTrends, TMXmoney, Morningstar, Market Screener, TradingView, Simply Wall St, Stockopedia, GlobeNewswire, GuruFocus, 4-Traders, Dividend.com, Stockhouse, and Nasdaq reported earlier on Diversicare Healthcare Services, Inc. (DVCR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Diversicare Healthcare Services, Inc. (as of September 4, 2019,) provides long-term care services to patients in 62 skilled nursing and senior housing centers containing 7,329 licensed nursing beds. The Company offers Short Stay Rehabilitation, Complex Medical Care, Long Term Care, Memory Care, Hospice Care, and Assisted Living. Diversicare has recognition as a premier provider of post-acute care and has a comprehensive team trained to administer high quality healthcare that meets patients needs. OTCQX-listed, Diversicare Healthcare Services has its corporate office in Brentwood, Tennessee.

The Company created and provides therapy powered by Diversicare Therapy Services (DTS). Its services incorporate current, evidence-based approaches to quality care and treatment in a safe environment. Diversicare Therapy Services’ (DTS’) team of talented and experienced therapists create customized rehabilitation programs based on an individual’s needs. Its physical, occupational and speech-language pathologists specialize in unique therapeutic approaches that focus on achieving an individual’s best outcomes.

Furthermore, in many centers, DTS offers outpatient services provided by the same therapists that assisted one in getting home. DTS has a team of more than 1,100 therapists.

Recently, Diversicare Healthcare Services announced its results for Q2 ended June 30, 2019. Commenting on the quarter, Jay McKnight, President and Chief Executive Officer, said, "Our primary update for the quarter is the announcement that we have reached an agreement in principle to settle the ongoing DOJ investigation into the Company’s therapy practices dating back to 2010. This investigation period predates our leadership team and has been a significant distraction for quite some time. We still have some work ahead of us to finalize the agreement and related Corporate Integrity Agreement, but reaching this agreement in principle represents substantial progress in resolving this matter. We ask that our investors please refer to our updated SEC filings for further information."

Last week, Diversicare Healthcare Services announced that effective August 30, 2019 it completed the transaction to transfer the operations of ten skilled nursing centers in the State of Kentucky. It finalized an agreement with Omega Healthcare Investors, Inc. (OHI) to amend its master lease to terminate operations of ten nursing facilities located in Kentucky, totaling roughly 885 skilled nursing beds, and to simultaneously transfer operations to an operator selected by Omega. Diversicare no longer operates any skilled nursing centers in Kentucky.

Diversicare Healthcare Services, Inc. (DVCR), closed Tuesday's trading session at $2.00, up 5.2632%, on 3,579 volume with 19 trades. The average volume for the last 3 months is 10,131 and the stock's 52-week low/high is $1.15999996/$2.0999999.

chart

Sunshine Biopharma, Inc. (SBFM)

Real Investment Advice, Insider Financial, Simply Wall St, Dividend Investor, Stockwatch, Investing.com, Trading View, Market Screener, GuruFocus, Stockopedia, Wallet Investor, All Stocks, InvestorsHub and Stockhouse reported beforehand on Sunshine Biopharma, Inc. (SBFM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma, Inc. is a pharmaceutical company headquartered in Pointe-Claire, Quebec. It focuses on the development of drugs for the treatment of aggressive types of cancer. In addition, the Company offers generic pharmaceuticals, Essential Brand dietary supplements, and certified analytical chemistry services. Sunshine Biopharma lists on the OTC Markets.

The Company operates via three subsidiaries. These are Atlas Pharma, Inc. (Testing Services); Sunshine Biopharma Canada, Inc. (Generic Drugs); and NOX Pharmaceuticals, Inc. (Propriety Drugs). Atlas Pharma offers certified testing services of pharmaceutical and other industrial samples. Generic drugs coming soon from Sunshine Biopharma Canada (not available in the U.S.) include SBI-Anastrozole for the treatment of Breast Cancer; SBI-Letrozole for the treatment of Breast Cancer; SBI-Bicalutamide for the treatment of Prostate Cancer; and SBI-Finasteride for the treatment of BPH (Benign Prostatic Hyperplasia).

Concerning Sunshine Biopharma’s Proprietary Drugs in development, its flagship anticancer drug is Adva-27a. This is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for different types of cancer. The expectation is that Adva-27a will enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection.

Moreover, Sunshine Biopharma has its dietary supplements product line - Essential 9™. This product contains all 9 essential amino acids in one tablet for maintaining and building muscle mass. In December of 2018, Sunshine Biopharma completed the development of Essential 9™.

On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9™ product. The Company has launched 7 new dietary supplements in addition to its original product, Essential 9™. The new products are BCAA; L-Carnitine; L-Creatine; L-Glutamine; Vitaminax; Omega 3; and Vitamin B12.

Last week, Sunshine Biopharma announced that it received Vegan Certification for Essential 9™ from VegeCert.com in association with Kashruth Council Of Canada. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions. This is from the musculature and immune system to hormones and neurotransmitters.

Sunshine Biopharma’s Essential 9 provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9 is suitable for everyone: vegans, athletes, seniors, as well as dieters.

Sunshine Biopharma, Inc. (SBFM), closed Tuesday's trading session at $0.0015, up 7.1429%, on 1,417,993 volume with 10 trades. The average volume for the last 3 months is 2,155,728 and the stock's 52-week low/high is $0.001399999/$0.0588.

chart

BioXyTran, Inc. (BIXT)

Born2Invest, Financial Buzz, Nasdaq, Avise Analytics, Wall Street Analyzer, Last10k, Proactive Investors, Investors Hangout, TradingView, Stockwatch, GuruFocus, Biospace, Simply Wall St, Wallet Investor, and Stockopedia reported beforehand on BioXyTran, Inc. (BIXT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, BioXyTran, Inc. centers on developing treatments for stroke and Ischemia. An early stage pharmaceutical company, it focuses on the development, manufacture, and commercialization of different therapeutic drugs to address hypoxia in humans. The Company’s lead pharmaceutical drug candidate is BXT-25. BioXyTran is based in Newton, Massachusetts.

BioXyTran has its BXT-25 and BXT-252. The design of both drugs are to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid. BXT-25’s co-polymer proprietary chemical structure acts as the main carrier of oxygen, instead of the Red Blood Cell that are blocked by the clot.

BXT-25 construct substantially reduces methemoglobin formation and nitric oxide scavenging, which may contribute to a variety of disorders, including renal failure, vasoconstriction, hypertension, myocardial infarction, and related toxicity issues. Furthermore, BXT-25’s small size, roughly 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries that are inaccessible to red blood cells because of clots or other obstructions.

BXT-25, in testing, will undergo evaluation as a resuscitative agent to treat strokes, particularly during the all-critical first hour following a stroke. The product will also undergo evaluation for its efficacy in treating other brain trauma issues.

The design of BioXyTran’s BXT-252 is to treat chronic wounds resulting from ischemia caused by occlusion of capillaries. BXT-252 has the same modality and physical properties as BXT-25. However, its proprietary co-polymer can improve the healing of pressure and arterial ulcers. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.

Hypoxic brain injuries, such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells, it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot.

Last month, BioXyTran announced that it has retained Dr. Hana Chen-Walden, MD, BIRA Diploma in Regulatory Affairs, to join the Company’s Scientific Advisory Board to assist designing the clinical trial protocol for BioXyTran’s flagship drug, BXT-25. Dr. Chen-Walden has more than 25 years of experience in clinical trial development. Dr. Chen-Walden worked at well-known Clinical Research Organizations (CRO)’s including Parexel, Covalent Group, and CRC before landing a consultancy position at EuClinReg Ltc.

BioXyTran, Inc. (BIXT), closed Tuesday's trading session at $0.84, up 5%, on 2,000 volume with 2 trades. The average volume for the last 3 months is 2,904 and the stock's 52-week low/high is $0.100000001/$1.95000004.

chart

Major Drilling Group International, Inc. (MJDLF)

24hgold, Street Insider, Market Screener, Invest Tribune, Capital Cube, Wallmine, 4-Traders, Wallet Investor, Northern Miner, Dividend Investor, Nasdaq, Stockhouse, and Morningstar reported earlier on Major Drilling Group International, Inc. (MJDLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Major Drilling Group International, Inc. provides contract drilling services for mining and mineral exploration companies in the United States, Canada, Mexico, South America, Asia, Africa, and Europe. As of April 30, 2019, it had a fleet of about 601 drilling rigs. Established in 1980, the Company is one of the world’s largest drilling services companies chiefly serving the mining industry. Major Drilling Group lists on the OTC Markets and the Company is based in Moncton, New Brunswick.

Major Drilling Group offers a suite of drilling services. These include surface and underground coring, directional, reverse circulation, sonic, geotechnical, environmental, water-well, coal-bed methane, shallow gas, underground percussive/longhole drilling, surface drill and blast, and diverse mine services.

Major Drilling Group offers services including mineral exploration, directional drilling, definition or infield drilling, mine development, dewatering, grade control, and percussive drilling for a producing mine. The Company’s environmental and sonic group can help sample tailings piles, monitor tailings dams, install grout curtains, and also install ground water sampling wells.

Yesterday, Major Drilling Group reported results for its Q1 of fiscal year 2020, ended July 31, 2019. Quarterly Revenue was $117.5 million. This represents an increase of 19 percent from the same quarter last year. Gross Margin percentage for the quarter was 26.1 percent, versus 23.8 percent for the corresponding period last year.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was up 78 percent to $18.0 million for the quarter versus the same period last year (the impact of IFRS 16 Leases was minimal at $0.3 million). As of Q1 2020, Major Drilling Group is reporting lease obligations according to IFRS 16, with right-of-use assets and lease liabilities reflected on its balance sheet and rent expense, previously reported in general and administrative expenses on the statement of operations, being replaced with interest and depreciation expense. Net Earnings were $6.0 million or $0.08 per share for the quarter, versus a Net Loss of $2.5 million or $0.03 per share for the previous year quarter.

Major Drilling Group International, Inc. (MJDLF), closed Tuesday's trading session at $4.35, up 14.1732%, on 3,675 volume with 23 trades. The average volume for the last 3 months is 5,532 and the stock's 52-week low/high is $2.92000007/$4.0300002.

chart

Mastermind, Inc. (MMND)

Zacks, TMXmoney, InvestorsHub, TipRanks, Street Insider, TeleTrader, Stockhouse, Stockwatch, YCharts, Stockopedia, OTC Markets, Market Wire News, Simply Wall St, and Market Screener reported previously on Mastermind, Inc. (MMND), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mastermind, Inc. is a leading involvement marketing agency headquartered in Atlanta, Georgia. The Company designs, creates and activates marketing campaigns for international brands. Mastermind has a complete, data-driven approach that drives brand consideration, trial, loyalty, as well as advocacy. The Company is a subsidiary of Mastermind Marketing, Inc. Mastermind lists on the OTC Markets Group’s OTCQB.

The Company has greater than 30 years’ of experience in dozens of industries helping involve people with brands in ways that inspire them to take action. Mastermind’s areas of expertise include Content, Digital, Influencer, Social, Promotion, Channel Optimization, and Digital Issues Management.

This allows the Company to create and execute multi-dimensional campaigns that drive results. Mastermind has a data-driven process. This involves strategy and planning - objective setting, goal establishment, data and market analysis.

Mastermind creates and manages digital content, social media and sharing campaigns, mobile merchandising, and communications and branding programs. Additionally, the Company designs websites. Mastermind designs, creates, and develops branding and marketing campaigns mainly for large corporate clients.

The Company is creating predictive analytic dashboards to optimize marketing decisions and drive more conversions for Fortune 500 brands. It aggregates and integrates disparate client data sources into custom algorithms to produce innovative dashboards that provide a tailored, on-demand, 360° view of the client’s business.

Last month, Mastermind announced financial results for the quarter and nine months ending June 30, 2019 that showed year over year growth in Revenue and Gross Profit. The Company had Net Income of $67,762 and $375,183 for the three month and nine month periods - the sixth consecutive quarterly profit. Total Revenues for the 9 months rose 8 percent from $3,670,474 to $3,949,398.

Gross Profit for the 9 months grew 9 percent from $3,138,444 to $3,405,262. Total Assets increased 14 percent from $2,130,568 to $2,418,783, and Stockholders' Equity increased 21 percent from $1,787,619 to $2,162,802.

Mastermind, Inc. (MMND), closed Tuesday's trading session at $1.45, up 16.00%, on 9,200 volume with 14 trades. The average volume for the last 3 months is 714 and the stock's 52-week low/high is $0.700100004/$6.00.

chart

MobileSmith, Inc. (MOST)

Zacks, Wallmine, GuruFocus, Capital Cube, Stockopedia, Stockwatch, Proactive Investors, Dividend Investor, Market Exclusive, YCharts, MarketWatch, Simply Wall St, Market Screener, Stockhouse, Wallet Investor, Last10k, InvestorsHub, Trading View, and 4-Traders reported earlier on MobileSmith, Inc. (MOST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MobileSmith, Inc. is a leader in the digital health and mobile development sector. It provides operational improvement member-facing mobile application (app) services to the healthcare industry in the U.S. The Company helps its clients improve health outcomes, patient satisfaction and increase profit margins utilizing its toolbox of proven mobile app technologies. The Company is changing healthcare one app at a time through targeting the evident inefficiencies in the U.S. healthcare delivery model. OTCQB-listed, MobileSmith is headquartered in Raleigh, North Carolina.

MobileSmith is helping its clients meet their healthcare consumers where they are, on their mobile devices, to expand the reach of providers to modify behavior with apps that remind, educate, track, and engage the patients that use them. The Company is concentrating on select patient segments that struggle with areas such as medication adherence, discharge instruction compliance, and health literacy, and provide new unique digital patient experiences including indoor navigation and clinic “check-ins” that directly improve critical patient satisfaction.

Through the use of MobileSmith Health Blueprints, hospitals and other healthcare organizations can customize their apps based on specific feature sets, workflow, branding, protocol, procedure and service line. This is while launching in as little as 90 days. MobileSmith Health announced recently the collaboration with Hardtner Medical Center on the release of a patient portal app - Hardtner Access. The Louisiana-based medical center turned to MobileSmith Health to develop its first app with the goal of increasing patient portal usage among its rural area patient population. The Hardtner Access App was built using MobileSmith Health’s signature Blueprints.

Recently, MobileSmith Health announced the appointment of Mr. Bruce Kennedy to its executive team. He is a healthcare marketing strategist with over two decades’ experience in multiple care delivery environments, including surgical patient safety and quality and digital hospital product development. Mr. Kennedy joins MobileSmith Health as Vice President of Provider Development.

In his role as Vice President of Provider Development, Mr. Kennedy will lead the expansion of new and existing hospital client and project growth and oversee client success operations and client application utilization. In addition, he will play a key role in the introduction of new products and projects into care delivery environments along with managing hospital operations and industry insight.

MobileSmith, Inc. (MOST), closed Tuesday's trading session at $1.85, up 2.7778%, on 679 volume with 1 trade. The average volume for the last 3 months is 679 and the stock's 52-week low/high is $0.75/$2.50999999.

chart

Two Rivers Water & Farming Company (TURV)

Zacks, Stockhouse, Daily Marijuana Observer, Marketbeat, NIC Investor, Wallet Investor, 4-Traders, TipRanks, Wallmine, and Cannabis FN reported earlier on Two Rivers Water & Farming Company (TURV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Two Rivers Water & Farming Company (TURV) owns a portfolio of water rights in the Arkansas River Basin in Colorado. The Company’s initial area of focus is in the Huerfano-Cucharas river basin in southeastern Colorado. Two Rivers assembles its water assets through acquiring land with senior water rights. It concentrates on the development and redevelopment of infrastructure for water management and delivery. OTCQB-listed, Two Rivers Water & Farming is headquartered in Aurora, Colorado.

At present, Two Rivers is centered on expanding its agriculture activity through growing hemp along with the development and rehabilitation of its water assets. It has two strategic focuses – GrowCo and Water Redevelopment Company.

Two Rivers Water & Farming Company announced on February 25, 2019, a potential purchase of three hemp-focused businesses – Vaxa Global, LLC; Ekstrak Labs LLC and Gramz Holdings, LLC (together Merged Companies), from the owner of the Merged Companies, EASBY Land & Cattle Company, LLC. The earlier announced acquisitions of the Merged Companies are on course for a single closing. However, the expected date of closure before June 1, 2019 was not attainable. The new anticipated date for closing is on or before July 31, 2019.

Vaxa Global distributes Canadian grown patented-processed hemp for CBD (cannabidiol) extraction within the U.S. to States approved to extract CBD. Vaxa plans to expand their agricultural activities to the Western U.S.

Ekstrak Labs, LLC is an emerging company in the extraction industry. Its dedication is to creating high quality extraction labs throughout the U.S. Eskstrak offers joint venture (JV) partnerships for brand diversification into different products that are top performers in the market.

Gramz Holdings is a top supplier, and first-to-market Nature’s Whole Spectrum™, natural whole plant compounds in delivery systems dedicated to maintaining the composition of the plant’s natural source and state. Gramzs’ products include Gramz Whole Plant Matrix™ Sublingual Drops and Gramz Herbal Topical and Gramz.

Two Rivers Water & Farming Company (TURV), closed Tuesday's trading session at $0.33, up 13.6755%, on 97,556 volume with 64 trades. The average volume for the last 3 months is 316,643 and the stock's 52-week low/high is $0.079999998/$0.735000014.

chart

Rezolute, Inc. (RZLT)

Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on Rezolute, Inc. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.

The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.

Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies.

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Recently, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute’s common stock at an implied per share price of $0.22.

Rezolute’s intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.

Rezolute, Inc. (RZLT), closed Tuesday's trading session at $0.15, up 15.3846%, on 19,100 volume with 18 trades. The average volume for the last 3 months is 6,683 and the stock's 52-week low/high is $0.090000003/$0.495999991.

chart

HedgePath Pharmaceuticals, Inc. (HPPI)

Simply Wall St, 4-Traders, Infront Analytics, Morningstar, MarketWatch, InvestorsHub, BUYINS.NET, Stockhouse, Dividend Investor, and Wallet Investor reported earlier on HedgePath Pharmaceuticals, Inc. (HPPI), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company headquartered in Tampa, Florida. It discovers, develops, and plans to commercialize front-line therapeutics for patients with cancer. The Company is looking to repurpose the Food and Drug Administration (FDA) approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HedgePath Pharmaceuticals lists on the OTC Markets Group’s OTCQB.

HedgePath is the exclusive United States licensee of a patented formulation of itraconazole, called SUBA-Itraconazole. Clinical studies have shown it to have more bioavailability than generic itraconazole. The Hedgehog signaling pathway is a significant regulator of cellular processes in vertebrates. This includes cell differentiation, tissue polarity, as well as cell proliferation.

The Company believes (based on published research) that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, HedgePath’s plan is to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization.

The design of “SUBA technology” (which stands for “Super Bioavailability”) is to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma. It has improved absorption and substantially reduced variability in comparison to generic itraconazole.

In August of 2018, HedgePath Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) confirmed HedgePath’s present clinical and regulatory pathway related to the Company’s SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, or Gorlin Syndrome).

Recently, HedgePath Pharmaceuticals announce that it entered into a revised Supply and License Agreement (SLA) with its majority stockholder Mayne Pharma Ventures Pty Ltd (Mayne Pharma), an affiliate of Mayne Pharma Group Limited. With the new SLA, Mayne Pharma will assume control of the regulatory and clinical development program for SUBA®-Itraconazole for the treatment of basal cell carcinoma nevus syndrome (SUBA-Itraconazole BCCNS) in expectation of conducting a worldwide Phase 3 pivotal clinical trial based on results attained in the Phase 2(b) trial conducted by HedgePath in the United States. Mayne Pharma will immediately assume responsibility for all future SUBA-Itraconazole BCCNS-related expenses.

HedgePath Pharmaceuticals, Inc. (HPPI), closed Tuesday's trading session at $0.868, up 33.54%, on 50,054 volume. The average volume for the last 3 months is 5,044 and the stock's 52-week low/high is $N/A/$N/A.

chart

iCo Therapeutics, Inc. (ICOTF)

Amigo Bulls, Wallet Investor, Zacks, Money Hub, Street Insider, InvestorsHub, Stockhouse, Capital Cube, TheMicrocapNews, The Hot Penny Stocks, Penny Stock Tweets, OTC Markets Group, Stockwatch, TradingView, Wall St Report, Vantage Wire, MarketWatch, GuruFocus, and Clever Markets reported earlier on iCo Therapeutics, Inc. (ICOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

iCo Therapeutics, Inc. identifies existing development stage assets for use in underserved ocular and infectious diseases. It owns the worldwide exclusive rights to an oral delivery system - Amphotericin B (Amp B) -for life-threatening infections. Amphotericin B is the gold standard for systemic antifungal drugs. It is one example of a well-established, highly efficacious systemic antifungal drug that has a 50-year history of intravenous therapy. OTCQB-listed, iCo Therapeutics is based in Vancouver, British Columbia.

The Company centers its efforts on development instead of research. iCo’s business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization, and develop them through redosing or reformulating them for new or expanded labels. iCo has its partnership with Immune Pharmaceuticals (IMNP), which is in a number of Phase 2 studies involving iCo-008. iCo-008 is also known as Bertilimumab or CAT-213.

iCo-008 is a human monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, which acts as a messenger between the cells of the immune system. Immune Pharmaceuticals initiated a Phase 2, double-blind, placebo-controlled study with iCo-008 in 90 patients with moderate-to-severe ulcerative colitis.

iCo Therapeutics continued to advance its Oral Amphotericin B Delivery System (Oral Amp B) in 2016. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections. The Company is developing a proprietary oral reformulation of Amphotericin B.

Recentlyr, iCo Therapeutics announced that it now has sufficient drug supply for a proposed mid-staged clinical trial that may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B) candidate. Moreover, based on discussions with anti-fungal experts, the Company’s intention is to conduct a comparison of oral Amp B to an approved azole drug in this proposed oral Amp B efficacy study in the area of women's health where recurrent candidiasis is common.

iCo’s licensee earlier announced a $5M USD financing for continued development of iCo-008. In addition, new clinical data has been reported in support of the drug candidate in bullous pemphigoid and pre-clinical data announced which is supportive of the potential use of iCo-008 in asthma.

iCo Therapeutics, Inc. (ICOTF), closed Tuesday's trading session at $0.1016, up 17.8654%, on 25,000 volume with 1 trade. The average volume for the last 3 months is 5,590 and the stock's 52-week low/high is $0.028999999/$0.092699997.

chart

MoneyOnMobile, Inc. (MOMT)

Stockflare, Marketwired, Stockopedia, Barchart, The Street, TradingView, YCharts, 4-Traders, OTC Markets, MarketWatch, InvestorsHub, and Morningstar reported on MoneyOnMobile, Inc. (MOMT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, MoneyOnMobile, Inc. is one of India's largest mobile phone-based payment networks. The Company facilitates easy, safe, and secure financial transactions to millions of Indians. Its core belief is in providing service to the unbanked consumer, by way of Financial Inclusion and self-dependence.

The Company previously went by the name Calpian, Inc. It changed its corporate name to MoneyOnMobile, Inc. in August 2016. Incorporated in 2006, MoneyOnMobile has offices in Dallas, Texas, and Mumbai, India.

The Company’s services include money transfer, mobile recharge, bill payment, DTH recharge, train tickets, flight tickets, hotel booking, and online shopping. It designed MoneyOnMobile to work across all mobile phone handsets. This is from the most basic to the most advanced.

MoneyOnMobile continually innovates to provide a range of innovative solutions together with its continuous, premier, 24 x 7 transactional convenience via a simple SMS, Application and Web Portal.  

MoneyOnMobile has authorization by the Reserve Bank of India (RBI) to set up a semi-closed payment system in India. This system enables registered users to buy goods, products, and services from registered Merchants.  MoneyOnMobile provides a broad array of services on a real-time basis, irrespective of geography, time, and mobile operator.

MoneyOnMobile previously announced the launch of the Reserve Bank of India's payment service (Bharat Billpay) through the MoneyOnMobile retailer platform. The launch of the new service enables its retailers to meet the growing demand for digital payment services among the estimated 600-800 million unbanked/underbanked population of India and increase the monthly spend of its existing customers.

Recently, MoneyOnMobile announced the number of MOM ATM units deployed in India has surpassed the 10,000-unit mark.

Mr. Harold Montgomery, MoneyOnMobile’s Chairman and Chief Executive Officer, said, "We are pleased with the progress of our MOM ATM deployments. Crossing the 10,000-unit mark demonstrates, we believe, strong demand for this product by our retailers. We are well on our way to reaching our goal of 30,000 MOM ATM units deployed by the end of 2019. This is the first step in the cycle of deployment activation and revenues.”

MoneyOnMobile, Inc. (MOMT), closed Tuesday's trading session at $0.0955, up 87.2549%, on 1,399 volume with 2 trades. The average volume for the last 3 months is 1,064 and the stock's 52-week low/high is $0.030549999/$1.75.

chart

Enertopia Corp. (ENRT)

Penny Stock General, Shiznit Stocks, Cannabis Financial Network News, PennyStocks24, Fast Money Alerts, Stock Shock and Awe, Penny Champions, Equities.com, MassiveStockProfits, Wall Street Equities Research, Stockgoodies, GrowthPennyStocks, and Penny Dreamers reported earlier on Enertopia Corp. (ENRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enertopia Corp. is exploring a portfolio of three prospective lithium projects in the State of Nevada. Additionally, at the same time, the Company is working with water purification technology believed to be able to recover Lithium from brine solutions. Enertopia has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

Enertopia announced in April 2017 the formation of a Lithium business division for the exploration of Lithium. In May 2017, it closed the definitive agreement for the Lithium exploration project in Nevada.

In June 2017, Enertopia announced its Surface Exploration Program in Nevada. In Nevada, the Company has 2,560 acres of placer mining claims staked in Edwards, Smith and Big Smoky valleys.

The Central Nevada Lithium Brine Projects are proximal to an existing lithium mine. There is all weather access on paved roads and it is an ideal evaporation climate.

Genesis Water Technologies (GWT) is a partner of Enertopia. GWT is a manufacturer of advanced, innovative and sustainable treatment solutions for applications in process water, drinking water, water reuse and waste water for the energy, agriculture processing, industrial, municipal infrastructure, and building/hotel sectors.

Since September 2017, GWT has been evaluating data obtained from the first bench test results and other technical data provided by Enertopia to complete a larger and enhanced lithium recovery system. This $200,000 pre-paid second phase bench test is now complete. The second phase of the second bench test will use synthetic brine solutions, which will be created from the surface samples from the two bulk samples taken at Enertopia’s Clayton Valley project.

The next steps for the Company in 2018 are a bench test build out this month and preparation of synthetic brines in February. In March and April, bench testing of synthetic lithium brines will take place. In May will be final laboratory lithium recovery and Li2CO3 grade results.

Enertopia Corp. (ENRT), closed Tuesday's trading session at $0.0109, up 9.00%, on 27,200 volume with 4 trades. The average volume for the last 3 months is 94,042 and the stock's 52-week low/high is $0.007/$0.035.

chart

Empire Petroleum Corp. (EMPR)

Nebula Stocks, OTC Markets, and The Street reported previously on Empire Petroleum Corp. (EMPR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Empire Petroleum Corp. engages in the exploration and development of oil and gas interests in North America. The Company owns interest in the Gabbs Valley prospect and interest in the South Okie prospect. The Gabbs Valley prospect is an area of roughly 34,186 gross acres in Nye and Mineral Counties, Nevada. The South Okie prospect encompasses 110 net acres of oil and gas leases in Natrona County, Wyoming. Established in 1983, Empire Petroleum has its corporate headquarters in Tulsa, Oklahoma.

The Company has conducted comprehensive geological studies, conducted a seismic survey, carried out a geochemical imaging survey, conducted satellite and gravity studies and drilled two test wells on the Gabbs Valley Prospect. The additional studies of such data and the assistance of geological and engineering consultants led Empire Petroleum to conclude that additional drilling was warranted. The determination was that a new test well should be drilled employing a different method of drilling.

Empire Petroleum drilled the Paradise Unit 2-12 well to a depth of 4,250 feet before drilling problems caused them to stop drilling. The Company assigned the lease and the 1-12 and 2-12 wells to the other leasehold owners from which Empire had taken a farmout. Empire Petroleum does feel the prospect has considerable geological merit since the main target, being the Triassic formation, was not reached in either of the two test wells.

Empire Petroleum and Sierra Nevada Oil, LLC concentrated their activities on the exploration and development of approximately 36,750 acres of Bureau of Land Management (BLM) leases positioned on a surface anticline in Gabbs, Nevada. Three exploratory wells were drilled on the leases.

In December 2016, Empire Petroleum announced that it entered into an Agreement (Contribution Agreement) with Masterson West, LLC, concerning a newly-formed entity, Masterson West II, LLC (MWII). Upon closing, Empire Petroleum will own up to a maximum of 50 percent of MWII if it delivers $18,000,000 with a proportionate decrease down to 25 percent of Masterson West II at the lower end of the range.

The oil and gas properties are in Moore and Potter Counties in the Texas Panhandle. The wells to be included in the transaction primarily target the Red Cave formation.

In September 2017, Empire Petroleum announced that it entered into a term sheet to acquire producing oil and gas assets in North Louisiana. The oil and gas properties are the East Haynesville and Oaks Fields in Claiborne Parish, Louisiana. The wells to be included in the transaction target the Pettit, Lower and Upper Haynesville, Cotton Valley and Smackover reservoirs.

Recently, Empire Petroleum announced that its Board of Directors retained Pritchard Griffin Advisors (PGA) to advise Empire on its potential NW Louisiana transaction and on other prospective mergers, joint ventures (JVs), and acquisitions for the Company.

Mr. Mike Morrisett, President of Empire Petroleum Corporation, said, “We are very pleased to have PGA engaged with the Company. Their breadth of experience, knowledge, and contacts in most of the major oil and gas basins in the U.S., specifically within the East Texas/Louisiana Cotton Valley/Haynesville play, provides the Company with the confidence to implement our initial strategy within this region.”

Empire Petroleum Corp. (EMPR), closed Tuesday's trading session at $0.1924, up 48.00%, on 100 volume with 1 trade. The average volume for the last 3 months is 5,407 and the stock's 52-week low/high is $0.100000001/$0.75.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis branded products company in the U.S., on Monday announced that PLPRF CEO and Board Member Jake Heimark will be presenting live at VirtualInvestorConferences.com on Thursday, September 12 at 1:30 PM ET. To view the live webcast, visit: http://nnw.fm/TM4zk. To view the full press release, visit: http://nnw.fm/f1BEn. Also today, the company was noted as among cannabis sector stake investments held by Belgravia Capital International Inc. (CSE:BLGV) (OTCQB:BLGVF) in an official Corporate Update.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $3.36, off by 1.2491%, on 13,313 volume with 49 trades. The average volume for the last 3 months is 36,944 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announces it has selected the corporate communications expertise of NetworkNewsWire ("NNW"). SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $3.07, up 2.6756%, on 55,075 volume with 317 trades. The average volume for the last 3 months is 106,582 and the stock's 52-week low/high is $1.54999995/$5.8499999.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of  scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers. 

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.97, up 7.6087%, on 44,031 volume with 120 trades. The average volume for the last 3 months is 10,601 and the stock's 52-week low/high is $1.25/$4.0999999.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to share that its portfolio company Herbert Works Ltd. ("Herbert Works") has received its research and development (R&D) licence from Health Canada to develop branded cannabis-infused beverages. Also today, the company was highlighted in an announcement by plant traits innovator focused on improving crop efficiency, ZeaKal, regarding that company’s recent collaborations with Canopy Rivers Inc. (TSXV: RIV, OTC: CNPOF) and Corteva Agriscience (NYSE: CTVA). Additionally, the company was highlighted in today's edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts http://ibn.fm/lY5EZ.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Tuesday's trading session at $1.9118, up 2.2353%, on 80,358 volume with 198 trades. The average volume for the last 3 months is 108,515 and the stock's 52-week low/high is $1.60000002/$7.30155992.

Recent News

chart

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Los Angeles-based Cannabis Strategic Ventures Inc. (OTC: NUGS) is proud to announce the first round of product sales from the inaugural harvest of its wholly owned and operated flagship greenhouse farm, NUGS FARM (www.nugsfarm.com), located in Northern California. The 6-acre cannabis operation is expected to reach full capacity by year-end and has started booking sales for more than 13 of its unique flower strains.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed Tuesday's trading session at $0.34, up 3.3435%, on 63,078 volume with 46 trades. The average volume for the last 3 months is 102,560 and the stock's 52-week low/high is $0.25/$4.84000015.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed Tuesday's trading session at $0.314595, up 3.8267%, on 203,031 volume with 66 trades. The average volume for the last 3 months is 229,565 and the stock's 52-week low/high is $0.189099997/$0.850000023.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) today announced results from its ongoing 2019 shallow diamond drilling program at its flagship nickel/cobalt development-focused Cyclops Project in Papua Province, Indonesia. To view the full press release, visit: http://nnw.fm/Bps8X.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed Tuesday's trading session at $0.1399, up 11.92%, on 134,125 volume with 22 trades. The average volume for the last 3 months is 30,041 and the stock's 52-week low/high is $0.070100001/$0.259299993.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

Innovative technology holding company VPR Brands (OTCQB: VPRB) this morning announced that it intends to create and execute a monetization and infringement enforcement plan for the company’s electronic cigarette utility patent US 8205622. To view the full press release, visit: http://nnw.fm/sePk9.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Tuesday's trading session at $0.081868, up 36.6745%, on 404,240 volume with 37 trades. The average volume for the last 3 months is 112,870 and the stock's 52-week low/high is $0.033799998/$0.119999997.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade (OTCQB: SGMD), a leading supplier of hydroponics and cultivation equipment and resources, this morning announced its new line of "iPower" branded inline duct ventilation fans. The advanced equipment for indoor and hydroponic cultivators is designed for durability, high-performance and affordability is now available for immediate purchase on the company's website at ZenHydro.com and on Amazon.com. To view the full press release, visit: http://nnw.fm/JjEK8.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.0121, up 9.009%, on 6,758,192 volume with 204 trades. The average volume for the last 3 months is 4,150,760 and the stock's 52-week low/high is $0.00975/$0.164000004.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, announces it has established a new sales division to sharpen its focus on CBD for therapeutic and pharmaceutical-grade products. Leading the division will be Erika Franck, who for several weeks has productively served as the Company’s clinical and therapeutics sales director. Also today, NetworkNewsWire released a report on the company detailing how ETST is quite unique in the oil sector, using proprietary supercritical CO2 liquid extraction, isolation and micron filtration process to manufactures 100 percent natural CBD oil. Additionally, ETST was featured today in the 420 with CNW by CannabisNewsWire.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Tuesday's trading session at $0.64, off by 7.2329%, on 118,238 volume with 77 trades. The average volume for the last 3 months is 61,973 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: A2PL), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced the closing of its acquisition of a 44,000 square foot cultivation, production and fulfillment facility located in Camp Verde, Arizona near Phoenix. To view the full press release, visit: http://nnw.fm/YSgS8.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Tuesday's trading session at $0.09, off by 7.1399%, on 858,834 volume with 109 trades. The average volume for the last 3 months is 62,971 and the stock's 52-week low/high is $0.082400001/$0.791499972.

Recent News

chart

Quest Patent Research Corp. (OTCQB: QPRC)

The QualityStocks Daily Newsletter would like to spotlight Quest Patent Research Corp. (OTCQB: QPRC).

Awareness about the monetization potential of intellectual property assets has increased over the past few years. This is one of the reasons why services like those provided by Quest Patent Research Corp. (OTCQB: QPRC) are expected to start playing an even bigger role in the corporate world in the years to come. Quest Patent Research is a New York-based intellectual property asset management firm that operates through majority-owned and controlled subsidiaries. These enable Quest Patent Research to deliver strategic, financial and legal resources to clients through its suite of value-added services.

Quest Patent Research Corp. (OTCQB: QPRC) is a New York City-based intellectual property (IP) asset management firm operating through majority-owned and controlled operating subsidiaries to deliver financial, strategic and legal resources for IP monetization. Quest currently owns, controls or manages over 115 patents across 11 intellectual property portfolios (https://www.qprc.com/portfolio). The company generates revenues from patent licensing fees of its IP property portfolios and from licensed packaging sales.

Quest creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets. Through its business, shareholders have the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space.

Objectives

Invention, protection and commercialization of IP require a deep understanding of dynamic technologies, market fundamentals, competitive landscapes and engagement strategies. Often, IP asset owners/stakeholders lack the requisite resources, experience and/or capacity to access the latent value of their IP assets and opportunities. Quest seeks to bridge this gap, partnering with asset owners – such as inventors, businesses, corporations and law firms – to help them fully realize the value of IP assets through:

  • IP Valuation
  • Structured Licensing Programs
  • Patent Prosecution
  • Partial or Full Liquidity
  • Portfolio Evaluation
  • Portfolio Maintenance
  • Legal Advisory
  • Attorney/Investor Referral
  • Patent Acquisition/Liquidation

At Quest, each partnership is treated as its own entity, with its own focused management comprised of Quest employees and seasoned industry associates. Many of technologies are placed in a wholly owned subsidiary of Quest, benefitting from the broader expertise of the company’s leadership.

Management

Quest’s management team delivers a wealth of experience in strategic business management, intellectual property, finance and marketing. The company’s internal resources, in tandem with its external network of financial, legal and managerial professionals, can develop creative solutions to the myriad of challenges involved in monetizing IP. Quest’s structured diligence and deployment procedures mitigate risks, maximize returns and deliver value to IP owners and shareholders alike.

Quest CEO and President Jon Scahill was the founder and managing director of the Urban-Rigney Group, LLC, a private consultancy specializing in new business/new venture development, operations optimization, and strategic analysis. Prior to launching his consultancy business, Mr. Scahill held numerous positions in sales and marketing, technical management, and product development in the consumer products/flexible packaging arena. Mr. Scahill holds a B.S. in chemical engineering from the University of Rochester, an MBA from Rochester’s Simon Graduate School of Business, and a JD from Pace University Law School. He is a registered patent attorney admitted to practice in New York, Florida, the District of Columbia and before the United States Patent and Trademark Office.

Quest Chief Technology Officer Timothy Scahill recently completed a merger and buyout of Managed Services Team LLC, an IT Managed Services provider. Prior to Managed Services Team, he was president of Layer 8 Group Inc., which merged with Structured Technologies Inc. to form Managed Services Team LLC. In his roles he was responsible for business strategy, acquisition, execution, as well as financial management. Mr. Scahill’s entrepreneurial acumen and proven record of successful management with sole discretionary responsibility, demonstrate the scope of his capability and his value to delivering results. He successfully completed his term on the boards of the Upstate New York Technology Council and Pariemus Rochester. Mr. Scahill completed a six-year term as secretary, executive council and a seat on the board of directors for Habitat for Humanity. He has served as president of the Western New York chapter of The Entrepreneurs Organization and continues to serve on the board as accelerator chair. Mr. Scahill is currently performing Cyber Intelligence, Security and Information Assurance work for an undisclosed organization.

Peter LaFauci is president of CFO Solutions, a Rochester, NY-based consulting firm offering knowledge-based financial and accounting solutions for emerging to medium-size companies. Mr. LaFauci is a seasoned executive with over 25 years of proven success in developing, leading and executing strategy in both publicly and privately held companies within the advertising, software development, internet, manufacturing and emerging technologies sectors. Peter possesses strong research and analytical skills as well as interpreting, summarizing and communicating financial and business information to others. Mr. LaFauci is a graduate of Saint Bonaventure University.

Quest Patent Research Corp. (OTCQB: QPRC), closed Tuesday's trading session at $0.0135, off by 10.00%, on 46,000 volume with 2 trades. The average volume for the last 3 months is 260,918 and the stock's 52-week low/high is $0.0013/$0.039999999.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint (OTCQB: SING) today provided shareholders an update on the success of Jacksam (OTCQB: JKSM), for which SING was a lead investor and able to secure a sizeable interest before the company went public and significantly increased in value. “To date, Jacksam has been a tremendous investment for SinglePoint. To view the full press release, visit: http://nnw.fm/6iHS9. Also today, NetworkNewsWire released a report on the company detailing how SING CEO Greg Lambrecht said in an interview on the RedChip Money Report that SING could realize a revenue trajectory rate from its Direct Solar of America division of $6­ million to $7 million in 2019 and $10 million to $12 million in the following 12 months. Keys to the impressive numbers, Lambrecht pointed out, have been the company’s expansion to larger commercial solar installations, the role of government state subsidies and available financing (http://nnw.fm/L7p18).

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.0125, off by 1.5748%, on 2,723,571 volume with 107 trades. The average volume for the last 3 months is 5,475,307 and the stock's 52-week low/high is $0.009999999/$0.041000001.

Recent News

chart

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Neutra Corp. (OTCQB: NTRR) (“Neutra” or “the Company”) has completed its previously announced acquisition of VIVIS Corp. (www.VivisCorp.com), a key move that provides the Company invaluable synergy and products as it gears up to enter the retail segment of the fast-growing U.S. CBD (cannabidiol) market.

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • Vivis – Neutra is expanding its market presence in the rapidly growing hemp-derived CBD market with a letter of intent to acquire Vivis, an emerging retail brand of hemp-based health and nutritional products. Vivis’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Tuesday's trading session at $0.0026, off by 10.3448%, on 36,182,104 volume with 204 trades. The average volume for the last 3 months is 22,299,724 and the stock's 52-week low/high is $0.0012/$0.100000001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.